🇺🇸 FDA
Pipeline program

LCAR- F33S cells intravenous infusion

LB2502-0001

Unknown mab active

Quick answer

LCAR- F33S cells intravenous infusion for Relapsed/Refractory Multiple Myeloma(MM) is a Unknown program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Relapsed/Refractory Multiple Myeloma(MM)
Phase
Unknown
Modality
mab
Status
active

Clinical trials